Trial Profile
A phase II/III randomized, observer-blind, controlled study to demonstrate non-inferior immunogenicity of a combined Tetanus-diphtheria-acellular Pertussis vaccine as compared to AdacelA vaccine in healthy subjects aged 12-17 years
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Jan 2019
Price :
$35
*
At a glance
- Drugs Pertussis acellular vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- 16 Dec 2018 According to a BioNet-Asia media release, one-year antibody persistence results from this study have been published in The Lancet Infectious Diseases (Nov 2018).
- 16 Dec 2018 Results presented in a BioNet-Asia media release.
- 28 Nov 2014 New trial record